obesity

BioSculpture Technology, Inc. establishes Obesity Control Research & Development Division

Robert Cucin MD JD MBA bariatric surgery, Diabetes, obesity, technology , , , ,

October 21, 2013 – BioSculpture Technology establishes the Obesity Control Research and Development Division.  The Division will consolidate and expand current efforts to develop improved methods and devices for the treatment of obesity, metabolic syndrome, and type 2 Diabetes mellitus.

2/3 of affluent populations are overweight and 1/3 are frankly obese.  43% of Developed World is forecast to be      obese in 10 years.  Obesity related chronic diseases account for 75% of overall healthcare spending.  Those diseases include type 2 Diabetes mellitus, hypertension, heart disease, gastric reflux, sleep apnea, autoimmune diseases and cancer.   Those diseases don’t just shorten lives, they reduce the quality of life.

80% of Type II Diabetics are obese. 1 out of 5 healthcare dollars is spent on Diabetes mellitus. Diabetes is the most frequent cause of kidney failure requiring dialysis and a frequent cause of blindness.

Already embarked on the goal of developing alternative bariatric treatments of obesity, metabolic syndrome and type II Diabetes mellitus, BioSculpture Technology has had three U.S. Patents allowed and has numerous U.S. and foreign Applications pending in this area.  

 

Campaign to Kick Start Development of Less Invasive Obesity Treatment

Robert Cucin MD JD MBA bariatric surgery, Diabetes, metabolic syndrome, obesity, technology , , ,

BioSculpture Technology, Inc. initiates a campaign to kick start development of the treatment contemplated by two recently issued U.S. patents to endoscopically removal visceral fat.

Visceral fat is a noxious hormone factory secreting cytokines which make obese and overweight patients insulin resistant and develop type 2 diabetes mellitus, hypertension, slows their metabolism, and promotes coronary artery disease, inflammatory diseases and cancers.  The literature and some early clinical studies have shown removing it has immediately beneficial effects in reversing those metabolic effects.

Please take the time to learn more about this and help us bring it to the 1.3 billion people whom it can benefit faster.

http://www.indiegogo.com/project/445739/widget/3646746

 

BST Aggressively Attacks Belly Fat

Robert Cucin MD JD MBA obesity, Uncategorized

Aggressively attacking belly fat, with Cinch It(TM) promotions, BST is currently selling products which allow improvement of the Waist-to-Hips Ratio (WHR) associated with metabolic syndrome, an increased incidence of coronary heart disease. and type II Diabetes Mellitus by removing fat outside the abdomen with TCAL LVL.  BST is also developing fourth generation twin cannula devices which will permit endoscopically guided, safe laparoscopic removal of the even more harmful visceral fat within the abdomen (Endoscopic Visceral Lipectomy or EVL) in a minimally invasive fashion and on January 20, 2012, BST received Notice of Allowance of  U.S. Patent Application #12/462,596 filed 8/5/09 and titled “Endoscopically-guided tissue aspiration system for safely removing fat tissue from a patient.”